FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316494279> ?p ?o ?g. }

• W4316494279 abstract "There is strong evidence that our current consumption of salt is a major factor in the development of increased blood pressure (BP) and that a reduction in our salt intake lowers BP, whether BP levels are normal or raised initially. Effective control of BP in people with diabetes lowers the risk of strokes, heart attacks and heart failure and slows the progression of chronic kidney disease (CKD) in people with diabetes. This is an update of a review first published in 2010.To evaluate the effect of altered salt intake on BP and markers of cardiovascular disease and of CKD in people with diabetes.We searched the Cochrane Kidney and Transplant Register of Studies up to 31 March 2022 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register were identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.We included randomised controlled trials (RCTs) of altered salt intake in individuals with type 1 and type 2 diabetes. Studies were included when there was a difference between low and high sodium intakes of at least 34 mmol/day.Two authors independently assessed studies and resolved differences by discussion. We calculated mean effect sizes as mean difference (MD) and 95% confidence intervals (CI) using the random-effects model. Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.Thirteen RCTs (313 participants), including 21 comparisons (studies), met our inclusion criteria. One RCT (two studies) was added to this review update. Participants included 99 individuals with type 1 diabetes and 214 individuals with type 2 diabetes. Two RCTs (four studies) included some participants with reduced overall kidney function. The remaining studies either reported that participants with reduced glomerular filtration rate (GFR) were excluded from the study or only included participants with microalbuminuria and normal GFR. Five studies used a parallel study design, and 16 used a cross-over design. Studies were at high risk of bias for most criteria. Random sequence generation and allocation concealment were adequate in only three and two studies, respectively. One study was at low risk of bias for blinding of participants and outcome assessment, but no studies were at low risk for selective reporting. Twelve studies reported non-commercial funding sources, three reported conflicts of interest, and eight reported adequate washout between interventions in cross-over studies. The median net reduction in 24-hour urine sodium excretion (24-hour UNa) in seven long-term studies (treatment duration four to 12 weeks) was 76 mmol (range 51 to 124 mmol), and in 10 short-term studies (treatment duration five to seven days) was 187 mmol (range 86 to 337 mmol). Data were only available graphically in four studies. In long-term studies, reduced sodium intake may lower systolic BP (SBP) by 6.15 mm Hg (7 studies: 95% CI -9.27 to -3.03; I² = 12%), diastolic BP (DBP) by 3.41 mm Hg (7 studies: 95% CI -5.56 to -1.27; I² = 41%) and mean arterial pressure (MAP) by 4.60 mm Hg (4 studies: 95% CI -7.26 to -1.94; I² = 28%). In short-term studies, low sodium intake may reduce SBP by 8.43 mm Hg (5 studies: 95% CI -14.37 to -2.48; I² = 88%), DBP by 2.95 mm Hg (5 studies: 95% CI -4.96 to -0.94; I² = 70%) and MAP by 2.37 mm Hg (9 studies: 95% CI -4.75 to -0.01; I² = 65%). There was considerable heterogeneity in most analyses but particularly among short-term studies. All analyses were considered to be of low certainty evidence. SBP, DBP and MAP reductions may not differ between hypertensive and normotensive participants or between individuals with type 1 or type 2 diabetes. In hypertensive participants, SBP, DBP and MAP may be reduced by 6.45, 3.15 and 4.88 mm Hg, respectively, while in normotensive participants, they may be reduced by 8.43, 2.95 and 2.15 mm Hg, respectively (all low certainty evidence). SBP, DBP and MAP may be reduced by 7.35, 3.04 and 4.30 mm Hg, respectively, in participants with type 2 diabetes and by 7.35, 3.20, and 0.08 mm Hg, respectively, in participants with type 1 diabetes (all low certainty evidence). Eight studies provided measures of urinary protein excretion before and after salt restriction; four reported a reduction in urinary albumin excretion with salt restriction. Pooled analyses showed no changes in GFR (12 studies: MD -1.87 mL/min/1.73 m², 95% CI -5.05 to 1.31; I² = 32%) or HbA1c (6 studies: MD -0.62, 95% CI -1.49 to 0.26; I² = 95%) with salt restriction (low certainty evidence). Body weight was reduced in studies lasting one to two weeks but not in studies lasting for longer periods (low certainty evidence). Adverse effects were reported in only one study; 11% and 21% developed postural hypotension on the low-salt diet and the low-salt diet combined with hydrochlorothiazide, respectively.This systematic review shows an important reduction in SBP and DBP in people with diabetes with normal GFR during short periods of salt restriction, similar to that obtained with single drug therapy for hypertension. These data support the international recommendations that people with diabetes with or without hypertension or evidence of kidney disease should reduce salt intake to less than 5 g/day (2 g sodium)." @default.
• W4316494279 created "2023-01-16" @default.
• W4316494279 creator A5051609819 @default.
• W4316494279 creator A5080132661 @default.
• W4316494279 date "2023-01-16" @default.
• W4316494279 modified "2023-10-01" @default.
• W4316494279 title "Altered dietary salt intake for preventing diabetic kidney disease and its progression" @default.
• W4316494279 cites W1945219173 @default.
• W4316494279 cites W1953196136 @default.
• W4316494279 cites W1975674493 @default.
• W4316494279 cites W1985854311 @default.
• W4316494279 cites W1994234198 @default.
• W4316494279 cites W1997242747 @default.
• W4316494279 cites W1997649883 @default.
• W4316494279 cites W1997902688 @default.
• W4316494279 cites W2006594891 @default.
• W4316494279 cites W2008304449 @default.
• W4316494279 cites W2012096008 @default.
• W4316494279 cites W2013216543 @default.
• W4316494279 cites W2022516965 @default.
• W4316494279 cites W2023531846 @default.
• W4316494279 cites W2024173171 @default.
• W4316494279 cites W2026681083 @default.
• W4316494279 cites W2027093473 @default.
• W4316494279 cites W2034469588 @default.
• W4316494279 cites W2034804577 @default.
• W4316494279 cites W2035617981 @default.
• W4316494279 cites W2041240844 @default.
• W4316494279 cites W2041405954 @default.
• W4316494279 cites W2056013702 @default.
• W4316494279 cites W2059804305 @default.
• W4316494279 cites W2085456568 @default.
• W4316494279 cites W2089002438 @default.
• W4316494279 cites W2100238516 @default.
• W4316494279 cites W2101612128 @default.
• W4316494279 cites W2104675861 @default.
• W4316494279 cites W2117077939 @default.
• W4316494279 cites W2121072148 @default.
• W4316494279 cites W2123831918 @default.
• W4316494279 cites W2125435699 @default.
• W4316494279 cites W2125436925 @default.
• W4316494279 cites W2128878016 @default.
• W4316494279 cites W2132984454 @default.
• W4316494279 cites W2135400982 @default.
• W4316494279 cites W2136808820 @default.
• W4316494279 cites W2141128448 @default.
• W4316494279 cites W2144043457 @default.
• W4316494279 cites W2144111789 @default.
• W4316494279 cites W2147056242 @default.
• W4316494279 cites W2148222582 @default.
• W4316494279 cites W2153899855 @default.
• W4316494279 cites W2153956648 @default.
• W4316494279 cites W2157692317 @default.
• W4316494279 cites W2165010366 @default.
• W4316494279 cites W2169842872 @default.
• W4316494279 cites W2172124430 @default.
• W4316494279 cites W2174508237 @default.
• W4316494279 cites W2254976155 @default.
• W4316494279 cites W2343076316 @default.
• W4316494279 cites W2390018839 @default.
• W4316494279 cites W2413410478 @default.
• W4316494279 cites W2505997306 @default.
• W4316494279 cites W2555588898 @default.
• W4316494279 cites W2557231117 @default.
• W4316494279 cites W2588681363 @default.
• W4316494279 cites W2750668636 @default.
• W4316494279 cites W2766154018 @default.
• W4316494279 cites W2800981650 @default.
• W4316494279 cites W2806758694 @default.
• W4316494279 cites W2916841405 @default.
• W4316494279 cites W2928467655 @default.
• W4316494279 cites W2972593364 @default.
• W4316494279 cites W2973096804 @default.
• W4316494279 cites W2996124557 @default.
• W4316494279 cites W3037046335 @default.
• W4316494279 cites W3040915988 @default.
• W4316494279 cites W3096486083 @default.
• W4316494279 cites W3133549572 @default.
• W4316494279 cites W3177322601 @default.
• W4316494279 cites W3198627281 @default.
• W4316494279 cites W4230425324 @default.
• W4316494279 cites W4245286889 @default.
• W4316494279 cites W4249259119 @default.
• W4316494279 cites W4252936472 @default.
• W4316494279 cites W65701506 @default.
• W4316494279 doi "https://doi.org/10.1002/14651858.cd006763.pub3" @default.
• W4316494279 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36645291" @default.
• W4316494279 hasPublicationYear "2023" @default.
• W4316494279 type Work @default.
• W4316494279 citedByCount "1" @default.
• W4316494279 countsByYear W43164942792023 @default.
• W4316494279 crossrefType "journal-article" @default.
• W4316494279 hasAuthorship W4316494279A5051609819 @default.
• W4316494279 hasAuthorship W4316494279A5080132661 @default.
• W4316494279 hasConcept C126322002 @default.
• W4316494279 hasConcept C127413603 @default.
• W4316494279 hasConcept C134018914 @default.
• W4316494279 hasConcept C147176958 @default.
• W4316494279 hasConcept C168563851 @default.
• W4316494279 hasConcept C2777180221 @default.

• next